Overview

Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer

Status:
Terminated
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
This trial will investigate the activity of dasatinib plus LHRH analogue therapy in high-risk localized prostate cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Noah Hahn, M.D.
Collaborator:
Bristol-Myers Squibb
Treatments:
Dasatinib
Leuprolide